Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017
February 22 2017 - 8:00AM
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, today announced that it will host a
conference call with members of Amarin senior management to discuss
the company's fourth quarter and full year 2016 financial results
and provide an operational update on Tuesday, February 28th, at
7:30 a.m. ET. The conference call will follow the anticipated
release of the company's financial results earlier that day.
Event details:The conference call can be heard
live on the investor relations section of the company's website at
www.amarincorp.com, or via telephone by dialing 877-407-8033 within
the United States or 201-689-8033 from outside the United States. A
replay of the call will be made available for a period of two weeks
following the conference call. To hear a replay of the call, dial
877-481-4010 (inside the United States) or 919-882-2331 (outside
the United States). A replay of the call will also be available
through the company's website shortly after the call. For both
dial-in numbers please use conference ID 10260.
To ask questions: During the teleconference,
following prepared remarks, management will respond to questions
from investors and analysts, subject to time limitations.
Participants in the live teleconference will be provided an
opportunity to ask questions. Investors may also e-mail their
questions to investor.relations@amarincorp.com. E-mail questions
will be accepted until 4:00 p.m. ET on Monday, February 27th,
2017.
About AmarinAmarin Corporation plc is a
biopharmaceutical company focused on the commercialization and
development of therapeutics to improve cardiovascular health.
Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits
of polyunsaturated fatty acids. Amarin's clinical program includes
a commitment to an ongoing outcomes study. Vascepa® (icosapent
ethyl), Amarin's first FDA approved product, is a highly-pure,
EPA-only, omega-3 fatty acid product available by prescription. For
more information about Vascepa, visit www.vascepa.com. For more
information about Amarin, visit www.amarincorp.com.
Availability of other information about
AmarinInvestors and others should note that Amarin
communicates with its investors and the public using its website
(www.amarincorp.com), its investor relations website
(http://www.amarincorp.com/investor-splash.html), including but not
limited to investor presentations and investor FAQs, U.S.
Securities and Exchange Commission filings, press releases, public
conference calls and webcasts. The information that Amarin posts on
these channels and websites could be deemed to be material
information. As a result, Amarin encourages investors, the media,
and others interested in Amarin to review the information that
Amarin posts on these channels, including Amarin’s investor
relations website, on a regular basis. This list of channels may be
updated from time to time on Amarin’s investor relations website
and may include social media channels. The contents of Amarin’s
website or these channels, or any other website that may be
accessed from Amarin’s website or these channels, shall not be
deemed incorporated by reference in any filing under the Securities
Act or under the Securities and Exchange Act of 1934, as
amended.
Amarin contact information:
Gene Mack
Executive Director, Investor Relations
Amarin Corporation
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries:
Kristie Kuhl
Finn Partners
In U.S.: +1 (212) 583-2791
Kristie.kuhl@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024